Calling from Ethiopia, where he was attending a mobile operators conference, Veremis said that what he sees in Africa and in other developing market is a leapfrog past the desktop phase that powered American companies like Dell and Gateway inthe 1990s.
The companies decided to end the program for developingthe compound, called Dimebon, after it failed to meet two primary endpoints in a phase 3 trial studying its use with the existing treatment Aricept in patients with mild-to-moderate Alzheimer's.